Designing Broad-spectrum Anti-HIV-1 GRNAs to Target Patient-derived Variants

Overview

Journal Sci Rep

Specialty Science

Date 2017 Nov 2

PMID 29089503

Citations 25

Authors

Will Dampier

Neil T Sullivan

Cheng-Han Chung

Joshua Chang Mell

Michael R Nonnemacher

Brian Wigdahl

Affiliations

Soon will be listed here.

Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR-associated protein 9 (Cas9), including specific guide RNAs (gRNAs), can excise integrated human immunodeficiency virus type 1 (HIV-1) provirus from host chromosomes. To date, anti-HIV-1 gRNAs have been designed to account for off-target activity, however, they seldom account for genetic variation in the HIV-1 genome within and between patients, which will be crucial for therapeutic application of this technology. This analysis tests the ability of published anti-HIV-1 gRNAs to cleave publicly available patient-derived HIV-1 sequences to inform gRNA design and provides basic computational tools to researchers in the field.

Citing Articles

Delivering CRISPR to the HIV-1 reservoirs.

Gurrola T, Effah S, Sariyer I, Dampier W, Nonnemacher M, Wigdahl B Front Microbiol. 2024; 15():1393974.

PMID: 38812680 PMC: 11133543. DOI: 10.3389/fmicb.2024.1393974.

Computational analysis of cas proteins unlocks new potential in HIV-1 targeted gene therapy.

Dampier W, Berman R, Nonnemacher M, Wigdahl B Front Genome Ed. 2024; 5:1248982.

PMID: 38239625 PMC: 10794619. DOI: 10.3389/fgeed.2023.1248982.

Assessment of anti-HIV-1 guide RNA efficacy in cells containing the viral target sequence, corresponding gRNA, and CRISPR/Cas9.

Allen A, Chung C, Worrell S, Nwaozo G, Madrid R, Mele A Front Genome Ed. 2023; 5:1101483.

PMID: 37124096 PMC: 10134072. DOI: 10.3389/fgeed.2023.1101483.

HIV-1 Reservoir Persistence and Decay: Implications for Cure Strategies.

Kreider E, Bar K Curr HIV/AIDS Rep. 2022; 19(3):194-206.

PMID: 35404007 PMC: 10443186. DOI: 10.1007/s11904-022-00604-2.

Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.

Mohamed H, Gurrola T, Berman R, Collins M, Sariyer I, Nonnemacher M Front Immunol. 2022; 12():816515.

PMID: 35126374 PMC: 8811197. DOI: 10.3389/fimmu.2021.816515.

References

Wang G, Zhao N, Berkhout B, Das A . A Combinatorial CRISPR-Cas9 Attack on HIV-1 DNA Extinguishes All Infectious Provirus in Infected T Cell Cultures. Cell Rep. 2016; 17(11):2819-2826. DOI: 10.1016/j.celrep.2016.11.057. View

Wang G, Zhao N, Berkhout B, Das A . CRISPR-Cas9 Can Inhibit HIV-1 Replication but NHEJ Repair Facilitates Virus Escape. Mol Ther. 2016; 24(3):522-6. PMC: 4786927. DOI: 10.1038/mt.2016.24. View

Tsai S, Zheng Z, Nguyen N, Liebers M, Topkar V, Thapar V . GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol. 2014; 33(2):187-197. PMC: 4320685. DOI: 10.1038/nbt.3117. View

Wu X, Scott D, Kriz A, Chiu A, Hsu P, Dadon D . Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells. Nat Biotechnol. 2014; 32(7):670-6. PMC: 4145672. DOI: 10.1038/nbt.2889. View

Kaminski R, Chen Y, Fischer T, Tedaldi E, Napoli A, Zhang Y . Elimination of HIV-1 Genomes from Human T-lymphoid Cells by CRISPR/Cas9 Gene Editing. Sci Rep. 2016; 6:22555. PMC: 4778041. DOI: 10.1038/srep22555. View

Kim V, Mears B, Powell B, Witwer K . Mutant Cas9-transcriptional activator activates HIV-1 in U1 cells in the presence and absence of LTR-specific guide RNAs. Matters (Zur). 2017; 2017. PMC: 5493433. DOI: 10.19185/matters.201611000027. View

Dampier W, Nonnemacher M, Mell J, Earl J, Ehrlich G, Pirrone V . HIV-1 Genetic Variation Resulting in the Development of New Quasispecies Continues to Be Encountered in the Peripheral Blood of Well-Suppressed Patients. PLoS One. 2016; 11(5):e0155382. PMC: 4873138. DOI: 10.1371/journal.pone.0155382. View

Limsirichai P, Gaj T, Schaffer D . CRISPR-mediated Activation of Latent HIV-1 Expression. Mol Ther. 2015; 24(3):499-507. PMC: 4786916. DOI: 10.1038/mt.2015.213. View

Saayman S, Lazar D, Scott T, Hart J, Takahashi M, Burnett J . Potent and Targeted Activation of Latent HIV-1 Using the CRISPR/dCas9 Activator Complex. Mol Ther. 2015; 24(3):488-98. PMC: 4786915. DOI: 10.1038/mt.2015.202. View

10.

Farasat I, Salis H . A Biophysical Model of CRISPR/Cas9 Activity for Rational Design of Genome Editing and Gene Regulation. PLoS Comput Biol. 2016; 12(1):e1004724. PMC: 4732943. DOI: 10.1371/journal.pcbi.1004724. View

11.

Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, Li F . RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proc Natl Acad Sci U S A. 2014; 111(31):11461-6. PMC: 4128125. DOI: 10.1073/pnas.1405186111. View

12.

Aiamkitsumrit B, Dampier W, Martin-Garcia J, Nonnemacher M, Pirrone V, Ivanova T . Defining differential genetic signatures in CXCR4- and the CCR5-utilizing HIV-1 co-linear sequences. PLoS One. 2014; 9(9):e107389. PMC: 4180074. DOI: 10.1371/journal.pone.0107389. View

13.

Wang Z, Pan Q, Gendron P, Zhu W, Guo F, Cen S . CRISPR/Cas9-Derived Mutations Both Inhibit HIV-1 Replication and Accelerate Viral Escape. Cell Rep. 2016; 15(3):481-489. DOI: 10.1016/j.celrep.2016.03.042. View

14.

C Antell G, Dampier W, Aiamkitsumrit B, Nonnemacher M, Jacobson J, Pirrone V . Utilization of HIV-1 envelope V3 to identify X4- and R5-specific Tat and LTR sequence signatures. Retrovirology. 2016; 13(1):32. PMC: 4855882. DOI: 10.1186/s12977-016-0266-9. View

15.

Kaminski R, Bella R, Yin C, Otte J, Ferrante P, Gendelman H . Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. Gene Ther. 2016; 23(8-9):690-5. PMC: 4974122. DOI: 10.1038/gt.2016.41. View

16.

Tsai S, Nguyen N, Malagon-Lopez J, Topkar V, Aryee M, Joung J . CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR-Cas9 nuclease off-targets. Nat Methods. 2017; 14(6):607-614. PMC: 5924695. DOI: 10.1038/nmeth.4278. View

17.

Yan M, Wen J, Liang M, Lu Y, Kamata M, Chen I . Modulation of Gene Expression by Polymer Nanocapsule Delivery of DNA Cassettes Encoding Small RNAs. PLoS One. 2015; 10(6):e0127986. PMC: 4452785. DOI: 10.1371/journal.pone.0127986. View

18.

Zhang Y, Yin C, Zhang T, Li F, Yang W, Kaminski R . CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep. 2015; 5:16277. PMC: 4633726. DOI: 10.1038/srep16277. View

19.

Yoder K, Bundschuh R . Host Double Strand Break Repair Generates HIV-1 Strains Resistant to CRISPR/Cas9. Sci Rep. 2016; 6:29530. PMC: 4941621. DOI: 10.1038/srep29530. View

20.

Huang Z, Nair M . A CRISPR/Cas9 guidance RNA screen platform for HIV provirus disruption and HIV/AIDS gene therapy in astrocytes. Sci Rep. 2017; 7(1):5955. PMC: 5519727. DOI: 10.1038/s41598-017-06269-x. View